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Cardiovascular complications are relevant due to their frequency and severity on the hypertension 
scenario. Studies refer Pharmaceutical Care (PC) as capable of decreasing cardiovascular risk rate 
(%CVR) on hypertensive patients. This study aimed to investigate, through a randomized clinical assay, 
the influence of PC service on the %CVR of hypertensive patients assisted in a health primary care 
unit from Fortaleza-Ceará. Two study groups were formed: i. Intervention Group (IG), which received 
orientation about taking medicines, actions aiming to prevent/solve medicine interactions and adverse 
effects and non-pharmacological interventions for 9 months and, ii. Control Group (CG), which received 
traditional assistance of the unit and was monitored during the same period. It was observed a statistically 
significant reduction on %CVR (10.76 to 7.86; p=0.04) and systolic blood pressure levels (SBP) (137.69 
to 131.54; p<0.01) in the IG, while, in the CG, there was no significant alteration. 151 Drug Related 
Problem (DRP) were identified and it was realized 124 pharmaceutical interventions, with 89.2% of 
them resulting on solution/prevention of the problem. Our findings indicated that the inclusion of the 
PC service in the hypertensive health assistance was more effective at the %CVR and the SBP reduction 
in comparison to the traditional assistance offered.
Uniterms: Pharmaceutical care. Cardiovascular risk. Hypertension.
As complicações cardiovasculares apresentam relevância devido à sua freqüência e gravidade no contexto 
da hipertensão. Estudos referem que a prestação do Cuidado Farmacêutico (CF) é capaz de reduzir a 
taxa de risco cardiovascular (%RCV) em hipertensos. Esse trabalho objetivou investigar, com um ensaio 
clínico randomizado, a influência da prestação do CF na %RCV em hipertensos atendidos em uma 
unidade de atenção primária à saúde de Fortaleza-Ceará. Formarm-se dois grupos de estudo: i. Grupo 
Intervenção (GI), que recebeu orientações sobre tomada dos medicamentos, ações visando prevenir/
resolver interações medicamentosas e reações adversas e intervenções não-farmacológicas por 9 meses 
e ii. Grupo Controle (GC), que recebeu assistência tradicional da unidade e foi monitorado durante o 
mesmo período. Observou-se redução estatisticamente significativa nas %RCV (10,76 to 7,86; p=0,04) 
e nos níveis de pressão arterial sistólica (PAS) (137,69 to 131,54; p<0,01) no GI, enquanto no GC, não 
houve alteração significativa. Identificaram-se 151 Problemas Relacionados com Medicamentos (PRM) 
e foram realizadas 124 intervenções farmacêuticas, das quais, 89,2% resultaram em solução/prevenção 
dos problemas. Nossos achados indicaram que a inclusão do serviço de CF na assistência ao paciente 
hipertenso foi mais eficaz na redução da %RCV e níveis de PAS em comparação à assistência tradicional.
Unitermos: Atenção Farmacêutica. Risco cardiovascular. Hipertensão.
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INTRODUCTION
Hypertension is a chronic disease characterized by a 
steady increase in blood pressure above normal rates, equal 
to or greater than 140 mmHg and 90 mmHg for the systolic 
and diastolic levels, respectively (Sociedade Brasileira de 
Cardiologia, 2010).
This is one of the largest causes of cardiovascular 
morbidity and mortality, being noticeably associated 
with the multifactorial etiology of ischemic heart 
disease, myocardial infarction, stroke alongside others 
cardiovascular events (Nobre, Coelho, 2013) and 
characterized as one of the biggest causes of reduced 
quality and life expectancy of individuals (Passos, Assis, 
Barreto, 2006).
In Brazil, according to DATASUS, it is estimated 
that there is a total of 16,934,611 hypertensive people 
and that at least 10% of this total had a cardiovascular 
complication. Also, until the end of 2012, more than 78,345 
hospitalizations were recorded with cases linked to essential 
hypertension (Brasil, 2013). The fact is that mortality in 
Brazil is still high compared to other countries, both for 
cerebrovascular disease and heart disease, complications 
known to be associated with hypertension (Brasil, 2009).
These facts draw attention to the importance of 
estimation of cardiovascular risk rate in hypertensive 
people. According to the VI Brazilian Guidelines on 
Hypertension (2010), the treatment strategy should 
be individualized according to the cardiovascular risk 
stratification as well as the goal of blood pressure 
level to be achieved. Therefore, strategies considering 
cardiovascular risk estimation and having its reduction as 
an ultimate outcome should be taken.
The Framingham Study has developed an estimate 
represented by the Framingham score, able to numerically 
predict the total risk of developing coronary artery disease 
which is used in several countries as a cardiovascular 
risk estimation tool (Mahmood et al., 2014). In Brazil, 
the Framingham risk scores estimate the absolute risk of 
coronary events in 10 years, generating points based on 
age, systolic and diastolic blood pressure, total cholesterol, 
HDL-cholesterol, smoking habit, and presence or absence 
of mellitus diabetes. After calculating the total points, the 
table of risks is taken into consideration for both sexes 
(Sociedade Brasileira de Cardiologia, 2013).
The role of the pharmacist as a health care provider for 
the general population and, in particular, for hypertensive 
patients, has been the subject of research worldwide. More 
than 70 randomized controlled trials published in English 
have reported this type of study (Roughead, Semple, Vitry, 
2003; Aguiar et al., 2012), where the authors present clinical 
benefits associated with the provision of pharmaceutical 
care services and management of blood pressure control in 
hypertensive patients. 
Some studies demonstrate the effectiveness of 
pharmaceutical care in dyslipidemia and the management 
of cardiovascular risk in hypertensive patients (Eizerik, 
Manfroi, 2008; Lyra Junior et al, 2011; Irons et al., 
2012; Firmino et al., 2012), obtaining statistically 
significant results in the reduction of cholesterol levels, 
cardiovascular risk rate and blood pressure levels.
Despite that, the scarcity of studies conducted in 
the country considering the cardiovascular risk rate as an 
important outcome with a well-defined methodological 
design is still evident (Simoni, 2009; Ambiel, Mastroianni, 
2013). This fact emphasizes the need for further scientific 
studies that assess the influence of pharmacotherapeutic 
monitoring in cardiovascular risk management in 
Brazil and collects epidemiological data in this context, 
particularly regarding the Northeast region of the country. 
Thus, the present study aimed to evaluate the 
influence of pharmaceutical care on cardiovascular risk in 
hypertensive patients registered in a Pharmaceutical Care 
Unit (PCU) of a Primary Health Care Unit in Region III 
of Fortaleza, Ceará, comparing with the traditional health 
care offered routinely.
MATERIAL AND METHODS
Type of study
This was a randomized clinical trial inserted in a 
real scenario of the national primary care practice and 
characterized by a pharmacotherapeutic follow-up of 
patients with the duration of nine months, structured 
with a “control” group and an “intervention” group in 
parallel formed by patients with the same characteristics. 
The collecting of the patients was performed in the first 
four months of the period of the study (October, 2011 to 
September, 2012).
The “intervention” group received pharmaco-
therapeutic follow-up (PTF) performed by a pharmacist 
trained in pharmaceutical care practice, which was regarded 
as the intervention in question, in addition to traditional care 
performed in the pharmacy unit of Dr. Anastacio Magalhães 
Primary Health Care (UAPS-AM). During the referred 
PTF, activities in health education, detection, resolution and 
prevention of drug related problems (DRP), and monitoring 
of adherence to prescribed treatment were provided to the 
participants. In turn, the “control” group was only monitored 
by the researcher during the nine months aiming to collect 
data for future comparison with the “intervention” group. 
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It is noteworthy that all activities relating to pharmaceutical 
care were made in the Pharmaceutical Care Unit (PCU) of 
UAPS-AM.
Selection of patients
The target patients were primarily those previously 
diagnosed with systemic hypertension who, in the 
first or subsequent appointments, had a) the existence 
of uncontrolled blood pressure and/or presence of 
cardiovascular risk factors, or b) difficult control and 
adherence problems to the treatment; or c) the need for 
education about the proposed pharmacotherapy and/or 
the use of two or more drugs for hypertension. These 
criteria were identified by the UAPS physicians, nurses 
and pharmacists of the dispensing pharmacy as well as 
by the team performing the present study after active 
dissemination of the study in the queues in the local 
pharmacy or in queues for medical appointments.
For this, the UAPS professionals were sensitized to 
this work, emphasizing the mechanisms for referral and 
counter-referral of patients. From established criteria, 
physicians, nurses and pharmacists could collaborate in 
the referral of patients to PCU.
The identified target patients were referred to the 
study team and then invited to participate, being led to 
the office designated for the PCU. In the office, the project 
was presented in more detail and the Free and Clarified 
Term of Consent (TC) was applied. After the acceptance 
and signature of the TC, the first interview scheduled by 
the researcher was started.
Those patients referred by health professionals, 
or invited by the performing team, who were not able to 
answer the questions of the pharmacotherapeutic record 
because of mobility or previously diagnosed mental 
disabilities, who had no conditions to attend the meetings 
when labeled, who reported participation in another 
intervention project in the same framework of this study 
were not enrolled. Those randomized to the intervention 
group who missed two consecutive meetings, resulting 
in four consecutive months of absence during follow-up 
were excluded.
This study did not use sample size calculation. The 
sample was formed by all patients of the UAPS who were 
referred to the PCU during the period established for 
patient enrollment in the present study.
Randomization
Both groups were determined by stratified 
randomization. All the participants were organized in 
subgroups according to sex and presence of cardiovascular 
risk factors such as Diabetes Mellitus, dyslipidemia and 
history of cardiovascular event. After that, four subgroups 
were formed (men without risk, men with risk, women 
without risk and women with risk) and each one was 
randomized with special care so that they remained as 
homogeneous as possible among themselves, in terms of 
size and characteristics, which could influence the final 
results.
The process was performed with the help of an 
unrelated person to the study. The toss of a coin was 
used as allocation mechanism with the unrelated person 
allocating the participants until the groups had the same 
number of patients from each subgroup. This process was 
concealed from the researcher of this study aiming to avoid 
bias in this specific procedure.
Instruments used
To implement the PTF the following instruments 
previously prepared by the staff members of the Center 
for Studies in Pharmaceutical Care (CEATENF), Federal 
University of Ceará (UFC), were used: an interview 
questionnaire, a development spreadsheet, an intervention 
planning worksheet, a timetable and a counter-reference 
tool. In addition to these instruments, the Framingham 
score table (Sociedade Brasileira de Cardiologia, 2013) 
was used to perform the calculation of cardiovascular risk 
of each patient included in the study by counting the points 
obtained in accordance with the parameters illustrated in 
that instrument. All these instruments were already being 
used in the service provided by PCU and were tested and 
optimized in a previous study (Firmino et al., 2012).
Data collection
The PTF was configured according to the Dáder 
method (Dáder, Hernández, Castro, 2014), as a method 
for clinical monitoring of patients with the follow-up type.
The pr imary outcome of  the  PTF was the 
cardiovascular risk rate. The influence of the PTF in this 
outcome was assessed from laboratory tests (glucose, 
total cholesterol and its fractions, and triglycerides) and 
blood pressure measurements, which, in turn, were used to 
calculate cardiovascular risk according to the Framingham 
score, performed at three time points: at the beginning of 
the PTF, after five months of follow-up and at the end of 
the study.
The results from laboratory tests as glycemia, total 
cholesterol, LDL, HDL and triglycerides and both systolic 
and diastolic blood pressure levels were considered as 
P. Y. M. Firmino, T. O. Vasconcelos, C. C. Ferreira, L. M. Moreira, N. R. Romero, L. A. Dias, M. G. R. Queiroz, M. V. O. Lopes, M. M. F. Fonteles620
secondary outcomes of the PTF. The laboratory tests 
were performed by collaboration from the Toxicology and 
Clinical Analysis Laboratory (LACT), Federal University 
of Ceará, at the beginning of the PTF period, after five 
months and at the end. The blood pressure measurements 
were performed by the study team following the method 
described in the Brazilian Hypertension Guidelines 
(Sociedade Brasileira de Cardiologia, 2010).
Further data was collected through interviews 
performed during the PTF.
Interviews
The interviews with patients included in the study 
were performed by members of the PCU team in an office 
reserved for such purpose. The average interval between 
interviews was two months, with the first subsequent 
interview occurring one month later, and they were marked 
during the previous interview and confirmed by phone the 
day before to minimize absence to the scheduled meetings. 
Thus, six interviews were scheduled for each patient of the 
‘intervention’ group.
The first one was reserved for the registration of 
the participant in the study, questionnaire completion 
and beginning of the PTF. All instruments were applied 
in this interview with the PCU team using all data 
collected to study each specific case, identifying DRP 
and elaborating interventions to solve or prevent them. 
During this interview the PCU team also provided general 
non-pharmacological information for hypertension control 
and cardiovascular risk factor management and corrected 
all evident adherence problems as well. These interviews 
averaged approximately 45 minutes and were carried out 
before randomization.
The subsequent interviews, called “return”, served 
for the continuation of the PTF, when was performed the 
evaluation of the outcomes from previously suggested 
interventions, identification and resolution of new 
DRP and the update of information obtained in the first 
interview also checking if the patients were able to apply 
the non-pharmacological orientation provided. Whenever 
the patients presented an improvement towards their 
therapeutic goals, the PCU team notified them with 
the objective of giving a positive feedback. In the third 
and last interview, as a differential, the participants 
were referred to the Toxicology and Clinical Analysis 
Laboratory (LACT), Federal University of Ceará, for 
new laboratory tests. The returns had an average time 
around 15-20 minutes.
In the case of the “control” group, the data collection 
after the first interview was through occasional meetings 
(equivalent to those meetings where the participants from 
the other group were sent to LACT for new tests) where 
there was only monitoring of the variables, for later 
comparison with the “intervention” group. The “control” 
group patients were also sent for laboratory tests, similarly 
to other participating patients. Therefore, the “control” 
group received the traditional health care assistance 
offered in the Health Care Unit during the follow-up 
months. The performing team did not aim to identify DRP 
during these interviews but it is important to highlight 
that the PCU team notified other health professionals if 
patients from this group presented major health problems 
at the moment.
In each interview the measurement of blood pressure 
levels was conducted by the performing team on both 
group participants and after the interviews, the DRP 
identified were classified and certified by the CEATENF/
UFC technical group following the 2nd Granada 
Consensus 2002 according to the referred study center 
routine, shown in Table I.
PCU was responsible for counter-reference, 
when appropriate. When the action to solve/prevent 
a DRP involved another health professional a brief 
written report was elaborated with the suggestion of 
pharmaceutical intervention and forwarded to the 
ones involved. Whenever possible the pharmaceutical 
intervention was discussed with the target of it in order 
to reach a consensus and ensure that it is applied and 
followed. It was ensured later if the intervention was 
accepted or not by the health professional involved or 
by the patient, if that was the case.
Data analysis
The groups were compared in relation to the results 
for the rate of cardiovascular risk, blood pressure levels 
and the relevant laboratory tests in its estimate.
The analysis of the results was performed after using 
the Statistic Package for Social Sciences (SPSS) 17.0 
version for Windows, using the paired t and McNemar 
tests for numerical and categorical variables, respectively. 
For all comparisons, a significance level of 5% was 
considered.
Ethical aspects
The study was designed according to the guidelines 
and rules for research involving human subjects and it 
was approved by the Ethics Committee in Research of 
the Federal University of Ceará - COMEPE (protocol 
number: 228/11).
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RESULTS AND DISCUSSION
From late October 2011 to late January 2012 
hypertensive patients were invited to participate in the 
study. 
Figure 1, above, shows the formation of the study 
sample from the beginning to the final group.
General data of the population
Table II shows the general characteristics of the 
study patients divided in two groups – “intervention” and 
“control” – in its baseline, also including relevant data to 
measure the rate of cardiovascular risk. The groups were 
considered homogeneous after due statistical tests.
Control group versus intervention group
An analysis of the differences obtained over the 
time in both groups (“control” group and “intervention” 
group), based on various clinical parameters, can be seen 
in Table III. 
The “intervention” group presented a reduction 
in the Framingham score and the rate of cardiovascular 
risk calculated during the study (1.24 points and 2.9%, 
respectively), showing a statistical difference (p<0.01 in 
both cases). In turn, the” control” group did not show the 
same tendency to reduction of the average of these values. 
When considering the parameters used for the 
cardiovascular risk evaluation, it was possible to 
observe some differences between the two study groups. 
Comparing the results of the pressure control of the 
groups, it was observed that the “intervention” group 
showed lower average in both systolic values (decrease of 
6.16 mmHg) and the diastolic (decrease of 2.69 mmHg), 
observing statistically significant differences in systolic 
values (p=0.04), while the “control” group showed no 
significant change. Additionally, it was observed an 
increase in the number of patients with controlled systolic 
levels going from 46.2% (n=12) to 65.4% (n=17) in 
“intervention” group while in “control” group there was 
not a significant change in this number (60%, n=18 to 
56.7%, n=17).
In both groups, the serum levels of the total and 
LDL cholesterol tended to decrease after the study. 
However, the reduction of the former was higher in the 
“intervention” group, whereas the reduction of LDL levels 
was higher in the “control” group. The change in HDL was 
different among patients in the two study groups, that is, 
the “intervention” group had a slight increase in serum 
levels at the end of the study, while the “control” group 
showed minimal variation to below the observed initial 
average. Comparing the variations in triglyceride levels 
TABLE I - Drug Related Problems classification (2nd Granada 
Consensus, 2002)
Classification Description
Necessity
DRP 1
The patient suffers from a health problem as 
a consequence of not receiving the medicine 
that he needs.
DRP 2
The patient suffers from a health problem as 
a consequence of receiving a medicine that he 
does not need.
Effectiveness
DRP 3
The patient suffers from a health problem 
as a consequence of a non-quantitative 
ineffectiveness of the medication.
DRP 4
The patient suffers from a health problem as a 
consequence of a quantitative ineffectiveness 
of the medication.
Safety
DRP 5
The patient suffers from a health problem as 
a consequence of a non-quantitative safety 
problem of the medication.
DRP 6
The patient suffers from a health problem as a 
consequence of a quantitative safety problem 
of the medication.
FIGURE 1 - Flowchart of the formation of the study sample 
(PCU-Anastácio Magalhães/October 2011 – September 2012).
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observed in the study groups, it was observed that the 
“intervention” group had a reduction of the initial average 
after nine months of follow-up. Finally, it was observed 
in both groups an increase in the average of glycemia at 
the end of the PTF, although the difference between the 
initial and final mean value was more pronounced in the 
“control” group than in the “intervention” group. 
The proportion of participants with controlled serum 
levels of these parameters changed as follows: the total 
cholesterol proportion decreased in the “intervention” 
group (61.9% to 52.4%) and increased in the “control” 
(53.3% to 73.3%); the controlled LDL proportion passed 
from 20% to 35% in the group under PTF while the other 
group dropped from 46.7% to 40%; it was observed a 10% 
increase on patients with at least 45 mg/dL of HDL after 
the nine months in the “intervention” group while there 
was no change in the other group proportion; patients with 
triglycerides at healthy levels represented 42.9% before 
TABLE II - Baseline characteristics of the study participants from both study groups (PCU-Anastácio Magalhães/October 2011 – 
September 2012)
Variable (n;%) Control (n=34) Intervention (n=34) P value
Female gender 26 (76.5) 26 (76.5) 1.00
Mean age (years) 60.7 59 0.48#
Diabetes Mellitus 12 (35.3) 10 (29.4) 0.60
Dyslipidemia 16 (47.1) 17 (50) 0.81
Patients who drink alcohol 04 (11.8) 07 (20.6) 0.32
Patients who are under diet 21 (61.8) 22 (64.7) 0.80
Previous cardiovascular event 09 (26.5) 12 (36.4) 0.38
Practice physical activity 14 (41.2) 16 (47.1) 0.62
Have a caretaker 05 (14.7) 07 (20.6) 0.52
Unlettered 00 02 (5.9) 0.15
Complete primary education 07 (20.6) 05 (14.7) 0.52
Complete secondary education 09 (26.5) 16 (47.1) 0.08
Complete major degree 03 (8.8) 03 (8.8) 1.00
Income ≤ 02 minimum wage 27 (79.4) 24 (70.6) 0.42
Can buy in a drugstore 24 (70.6) 28 (82.4) 0.25
P value determined by Chi-square test. #t test was performed.
TABLE III - Comparison of the results (mean) obtained in the study groups (total n = 56) at the end (PCU-Anastácio Magalhães/
October 2011 – September 2012)
Variable
Control (n=30) Intervention (n=26)
BL 9 months P value  BL 9 months  P value
SBP (mmHg) 132 136.33 0.12 137.69 131.54 0.04#
DBP (mmHg) 79.67 83.67 0.06 81.92 79.23 0.11
Framingham Score (points)* 15.93 16.26 0.35 15.67 14.42 <0.01#
Cardiovascular Risk Rate (%)* 6.2 6.86 0.36 10.76 7.86 <0.01#
Total Cholesterol (mg/dL)* 196 184.27 0.40 221.09 195.67 0.14
LDL (mg/dL)* 120.6 109 0.34 127.03 122.24 0.54
HDL (mg/dL)* 44.6 44.33 0.90 39.57 42.62 0.09
Triglycerides (mg/dL)* 153.67 161.73 0.57 248.76 204.43 0.35
Glycemia (mg/dL)* 110.73 120.4 0.08 100.71 103.24 0.62
*Control group, n=15 e intervention group, n=21; #presented statistical significance after t Student test was performed. BL = 
Baseline; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure.
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the PTF e after it represented 57.1% of the group, the 
“control” group proportion also increased from 53.3% to 
60%; the proportions regarding glycemia remained the 
same on both groups.
Drug related problems and pharmaceutical 
interventions
A total of 151 DRP were detected and classified in 
the study population (n = 68). Among the DRP detected, 
the most frequent was ineffectiveness quantitative 
(DRP 04, n = 48, 31.8%), followed by DRP 03, i.e. non-
quantitative ineffectiveness of the medication (n = 43, 
28.5%), DRP 05, non-quantitative safety problem of 
the medication (n = 32, 21.2%), and DRP 01, related to 
problems due to the non-use of necessary medication (n 
= 23, 15.2 %). Problems associated with overdose (DRP 
06) and the use of unnecessary medications (DRP 02) were 
the least frequent (DRP 06: n = 4, 2.6%; DRP 02: n = 1, 
0.7%), respectively (Figure 2).
Regarding the type of DRP (whether potential 
or real), the most frequent one was real with 65.6% of 
incidence, equivalent to an n of 99 out of the whole 151, 
with the potential type representing 34.4% (n = 52).
Of the 151 DRP identified, there was a pharmaceutical 
intervention in 124 (82.1%) – the patient / user accepted the 
proposed intervention in all cases. In 71% of them (n=88) 
written information was delivered to the intervention 
target alongside verbal reinforcement so the PCU team 
could ensure the intervention was understood, with one 
case involving a successful written solicitation regarding 
necessary changes in the prescription to the physician.
The interventions realized during the PTF included 
“suggestion to reconsider prescribed dose of a medicine” 
(n=4), “alert about not taking a prescribed medicine” 
(n=16), “correction of taking medicine process problems” 
(n=83), “alert of potential or manifested medication 
adverse effects” (n=19) and “others” (n=2).
After the completion of the interventions, it was 
possible to evaluate the outcome of 74 of them, which 
equates to 59.7% of the total 124. Most of these 74 
interventions (n=66, 89.2%) resulted in resolution or 
prevention of the problem presented by the patient / user, 
be it related to health or lack of information / education.
DISCUSSION
Our findings denoted a significant reduction in 
systolic blood pressure between the two-time points 
analyzed for the Intervention group, reaching a particular 
therapeutic objective (Sociedade Brasileira de Cardiologia, 
2010). In turn, the “control” group showed no reduction 
in the systolic blood pressure. One can then infer that the 
pharmaceutical care was able to positively influence the 
reduction of systolic blood pressure values of the assisted 
patients/users, as inferred in previous studies (Lyra Junior 
et al, 2011; Firmino et al., 2012; Plaster, Melo, 2012; Zhao 
et al., 2012; Morgado, Rolo, Castelo-Branco, 2011).
A reduction from the initial value of diastolic 
blood pressure levels and consequently compliance with 
established therapeutic goal was observed, while in the 
“control” group, the same pattern was not observed. 
However, statistical tests did not confirm the hypothesis 
that the reduction was due to pharmaceutical intervention, 
which may be justified by the fact that the average 
initial levels were already near therapeutic target of 80 
mmHg (Sociedade Brasileira de Cardiologia, 2010). 
This fact hinders the observation of sufficiently large 
difference between the values so that there was statistical 
significance, considering the number of study patients. 
Probably in a study with a larger number of participants 
or that included only hypertensive patients with both 
uncontrolled systolic and diastolic blood pressure levels 
a statistically significant difference would have been 
observed as showed in previous studies (Lyra Junior et 
al, 2011; Plaster, Melo, 2012; Morgado, Rolo, Castelo-
Branco, 2011). Although this fact was also reported before 
(Firmino et al., 2012; Al Mazroui et al., 2009).
There was a statistically significant reduction in 
cardiovascular risk in the “intervention” group while 
the “control” group showed no significant change in 
the average rate of cardiovascular risk after the study 
period. These results were shared by other studies that 
evaluated the effect of a pharmaceutical intervention 
FIGURE 2 - Frequency of the DRP identified (2nd Granada 
Consensus), total=151 (PCU-Anastácio Magalhães/October 
2011 - September 2012).
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on cardiovascular risk in other countries (Al Mazroui et 
al., 2009; Zhao et al., 2012; Amariles et al., 2012) and 
in Brazil (Lyra Junior et al., 2011; Firmino et al., 2012; 
Plaster, Melo, 2012; Martins, Aquino, 2013).
This way, the pharmaceutical care provided during 
the period of the study proved possible to establish a 
strategy to impact on cardiovascular risk management 
in hypertensive patients, being an intervention with 
immediate clinical benefit and preventive of escalations 
related to cardiovascular events compared to traditional 
health care offered to these patients.
The results regarding the changes in the average of 
the levels of total cholesterol and LDL and HDL fractions 
of the “intervention” group showed tendency to positive 
results, with variation of average values closer to therapeutic 
targets. In the “control” group, reductions in average of 
total cholesterol and its LDL fraction were also identified; 
however, the average of HDL had a minimal variation 
to below the initial value, unlike the group under PTF. 
Unfortunately, none of these changes achieved statistical 
significance, going against the results reported in a review 
(Eizerik, Manfroi, 2008) and more recent studies done in 
the country (Lyra Junior et al., 2011; Plaster, Melo, 2012).
Despite no statistical proof and the observation of a 
drop in the proportion of patients with controlled levels, 
it is noteworthy that, in the case of the average total 
cholesterol level in the “intervention” group, the average 
value achieved the therapeutic objective for this parameter 
(Sociedade Brasileira de Cardiologia, 2013) at the end of 
the study, indicating a potential clinical benefit related to 
the intervention performed in this work.
The results of the levels of triglycerides and glucose 
showed no conclusive results in the study groups. The 
studies with beneficial results on those indexes usually 
adopt a longer PTF than employed in our study, and that 
may be a determinant for such purpose (Lyra Junior et al. 
2011; Al Mazroui et al., 2009; Chung et al., 2014; Collins 
et al., 2011).
The most frequently identified DRP during the 
PTF were the DRP 04, 03 and 05. These results are in 
line with DRP’s profile identified in studies conducted 
in Brazil (Dall’Agnol, 2004; Netto, Melo, Silva, 2005; 
Alano, Corrêa, Galato, 2012), predominating, especially 
problems of therapeutic ineffectiveness. Many of these 
problems were related to the non-adherence to treatment 
by the patients, a behavior frequently identified among 
hypertensive patients due to the need for chronic therapy 
and the asymptomatic disease profile (Manfroi, Oliveira, 
2006; Pucci et al., 2012).
The DRP 05 had relatively high incidence probably 
due to the average age of the study population to 
be approximately 60 because, according to studies 
(Dall’Agnol, 2004), this population is more susceptible 
to non-safety DRP, represented mainly by adverse events.
The identification of DRP 02 in our study was also 
observed in other studies conducted in Brazil (Dall’Agnol, 
2004; Alano, Corrêa, Galato, 2012), but in a higher number 
of registered cases. In our study, this smaller number of 
records may be due to the limitation of the identification 
method for problems used, mainly depending on the self-
report of the participants who, when asked if they used 
non-prescription medicines, they responded that they only 
used prescribed drugs, with some exceptions. This fact 
may have led to an underestimation of self-medication, 
a habit known in the Brazilian population (Arrais et al., 
1997; Sousa, Silva, Neto, 2008; Mastroianni et al., 2011).
Unfortunately, not every DRP identified had an 
intervention made with the purpose to solve or prevent 
it since some of those problems were related to eventual 
medicine shortages occurring in the Health Care Unit 
so the PCU team could not handle it. Also, not every 
intervention had its outcome evaluated because some of 
them were applied during the first interview of patients 
who were later allocated in the “control” group, which the 
PCU team was going to meet again just around five months 
later, considered late to associate any effect observed to 
the intervention suggested.
 Nevertheless, in our study, several pharmaceutical 
interventions were used, aiming the prevention / resolution 
of DRP identified and, finally, approximately 90% of them 
had the expected outcome, i.e., they were able to solve 
or prevent the incident, a percentage similar to a study 
conducted in Santa Catarina (Alano, Corrêa, Galato, 
2012). A few of the interventions did not result in solution/
prevention of the problem sometimes because the patient 
could not follow the orientation during his daily routine 
or because the other professional did not agree with the 
strategy suggested. In those cases, a new intervention was 
elaborated and suggested.
It is noticeable that the vast majority of the 
interventions had the patient as its target and focused on 
adherence problems resolution as it was the main cause for 
therapeutic ineffectiveness found in our study. This might 
suggest that most problems could be prevented if there 
was a health professional responsible for identifying and 
solving potential problems with taking medicines.
Furthermore, the authors highlight that the research 
was conducted in a previously established PCU in a 
Health Care Unit by CEATENF. This PCU was initiated 
in November 2008 and since then has been providing 
pharmaceutical care for hypertensive and diabetic patients 
as a routine. This study is a result of a real scenario 
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pharmaceutical care service and is seen as a step further 
towards the complete establishment of pharmaceutical 
care practice in Health Care Units routine.
As a limitation of this study, it is important to 
highlight that the local people are still reluctant, at times, 
to understand the benefits of a guidance-oriented service 
on pharmacotherapy and issues related to the prevention 
of exacerbations of chronic diseases such as hypertension, 
which limited the number of patients willing to participate 
in the study. Moreover, the non-compliance, as a whole, of 
the other UAPS professionals, including pharmacists, to 
our survey resulted in a low number of patients referred to 
the study, were obstacles to the practice of pharmaceutical 
care previously reported (Oliveira et al., 2005). Finally, 
another limiting factor that hindered data collection 
compared to the rate of cardiovascular risk was that some 
participants did not go to LACT for blood collection and 
examinations required.
CONCLUSIONS
Given the results described and discussed, we 
conclude that the characteristics of the local population 
assisted by the primary health care show that it is necessary 
to institutionalize a guidance-oriented and monitoring 
service aimed to guarantee the effectiveness and safety 
of prescribed pharmacotherapy because there is still a lot 
of need for information on the subject to this population, 
which hinders the success of the treatment.
Our study suggests that the implementation 
of a pharmacotherapeutic follow-up of nine months 
for hypertensive patients has a positive impact on 
cardiovascular risk management compared to traditional 
health care provided by primary care. This reinforces that 
the exercise of clinical and health care activities directly 
targeting the hypertensive patient by the pharmacist, in 
partnership with the multidisciplinary team, is able to 
benefit blood pressure control thereof, especially when 
considering the systolic levels.
In addition, during the pharmacotherapeutic follow-
up, several problems related to drug use were identified 
and prevented / resolved as pharmaceutical interventions 
were carried out comprising recommendations to the 
health care professionals, reinforcements about the 
prescribed therapy and educational interventions to the 
patients. Such pharmaceutical interventions were largely 
accepted in general. Thus, it emphasizes the importance 
of the provision of pharmaceutical care to hypertensive 
patients in relation to the improvement of the current 
health status and the prevention of future cardiovascular 
complications in different health care scenarios.
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